WO2023068363A1 - 脳萎縮抑制剤、脳萎縮の抑制方法、培養物、培養物の使用、飲食品、脳萎縮抑制用食品、脳萎縮抑制用サプリメント、及び脳萎縮抑制用医薬 - Google Patents
脳萎縮抑制剤、脳萎縮の抑制方法、培養物、培養物の使用、飲食品、脳萎縮抑制用食品、脳萎縮抑制用サプリメント、及び脳萎縮抑制用医薬 Download PDFInfo
- Publication number
- WO2023068363A1 WO2023068363A1 PCT/JP2022/039307 JP2022039307W WO2023068363A1 WO 2023068363 A1 WO2023068363 A1 WO 2023068363A1 JP 2022039307 W JP2022039307 W JP 2022039307W WO 2023068363 A1 WO2023068363 A1 WO 2023068363A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subjects
- brain atrophy
- ferm
- bifidobacterium breve
- atrophy
- Prior art date
Links
- 208000024806 Brain atrophy Diseases 0.000 title claims abstract description 123
- 235000013305 food Nutrition 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 20
- 239000003795 chemical substances by application Substances 0.000 title claims description 14
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title description 30
- 239000013589 supplement Substances 0.000 title description 15
- 235000013361 beverage Nutrition 0.000 title description 6
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 93
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 88
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 52
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 42
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 41
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 230000006999 cognitive decline Effects 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 24
- 206010008096 Cerebral atrophy Diseases 0.000 claims description 23
- 241000186000 Bifidobacterium Species 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 230000001629 suppression Effects 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 208000028698 Cognitive impairment Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000020299 breve Nutrition 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 abstract description 22
- 206010012289 Dementia Diseases 0.000 description 30
- 208000024827 Alzheimer disease Diseases 0.000 description 19
- 206010003694 Atrophy Diseases 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000037444 atrophy Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 238000002372 labelling Methods 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 230000006872 improvement Effects 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004278 EU approved seasoning Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000013611 frozen food Nutrition 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 230000008449 language Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004727 amygdala Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 206010016880 Folate deficiency Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000002667 Subdural Hematoma Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940005524 anti-dementia drug Drugs 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 208000013677 cerebrovascular dementia Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940079866 intestinal antibiotic Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 230000006016 thyroid dysfunction Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000589586 Empedobacter brevis Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014613 canned/preserved soup Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000010326 executive functioning Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Definitions
- the present disclosure relates to an agent for suppressing brain atrophy, a method for suppressing brain atrophy, a culture, use of the culture, food and drink, a supplement for suppressing brain atrophy, and a medicine for suppressing brain atrophy.
- Patent Document 1 describes dementia and depression using a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) and/or Bifidobacterium breve MCC1274 (FERM BP-11175) as an active ingredient. , schizophrenia, delirium, amnesia, cognitive decline, and brain function improving agent for the prevention, treatment and / or improvement of one or more brain function decline selected from the group consisting of intellectual disability disclosed.
- Dementia is caused by various disorders caused by the death of brain cells or deterioration of their function due to various causes, such as inability to make judgments and rapid deterioration of memory. It refers to a state in which life is continuously disturbed.
- the most common causes of dementia are neurodegenerative diseases in which nerve cells in the brain slowly die, followed by cerebrovascular dementia.
- the neurodegenerative diseases include Alzheimer's disease, frontotemporal dementia, and Lewy body dementia.
- Cerebrovascular dementia is caused by cerebral infarction, cerebral hemorrhage, cerebral arteriosclerosis, or the like, which leads to death of brain nerve cells or destruction of nerve networks.
- Alzheimer's disease is a neurodegenerative disease that accounts for 50%-60% of dementias.
- Alzheimer's disease Neuropathological hallmarks of this Alzheimer's disease are neurofibrillary degeneration in the cerebral cortex and hippocampus, senile plaques and massive neuronal loss. Neurofibrillary degeneration is caused by excessive phosphorylation of tau protein, which is one of microtubule-associated proteins, to form fibril inclusions. Senile plaques are extracellular accumulations of amyloid ⁇ -protein. In Alzheimer's disease, accumulation of this amyloid- ⁇ protein accelerates neurofibrillary degeneration, and fibrillated tau protein inhibits intracellular transport. Furthermore, the amyloid ⁇ protein itself has cytotoxicity such as synaptic dysfunction.
- MCI Mild Cognitive Impairment
- the present disclosure suppresses the progression of brain atrophy in any subject selected from healthy subjects, subjects diagnosed with mild cognitive impairment, subjects evaluated to have cognitive decline, and subjects at risk of suffering from neurodegenerative diseases.
- An object of the present invention is to provide an agent for suppressing brain atrophy, a method for suppressing brain atrophy, a culture, or use of the culture.
- One aspect of the present disclosure is administered to any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject assessed as having cognitive decline, and a subject at risk of suffering from a neurodegenerative disease , and Bifidobacterium breve MCC1274 (FERM BP-11175).
- Another aspect of the present disclosure is that an effective amount of a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for suppressing brain atrophy is administered to healthy subjects who need to suppress brain atrophy, subjects diagnosed with mild cognitive impairment, cognitive function
- a method for suppressing cerebral atrophy comprising administration to a subject selected from subjects evaluated as declining and subjects at risk of suffering from a neurodegenerative disease.
- Yet another aspect of the present disclosure is the brain of any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject assessed for cognitive decline, and a subject at risk of suffering from a neurodegenerative disease.
- 1 is a provision of a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for use in inhibiting atrophy.
- Yet another aspect of the present disclosure is administering to any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject evaluated for cognitive decline, and a subject at risk of suffering from a neurodegenerative disease and the use of a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for the manufacture of a brain atrophy-suppressing agent.
- a cerebral atrophy inhibitor a method for inhibiting cerebral atrophy, a culture, or use of the culture are provided. Note that the effects described here are not necessarily limited, and may be any of the effects described in this specification.
- FIG. 1 is a graph showing changes in the VSRAD score of each subject (A: Bifidobacterium ingestion group, B: Placebo ingestion group).
- FIG. 2 shows representative MRI images of subjects (A: Bifidobacterium ingestion group, B: Placebo ingestion group).
- Brain atrophy refers to characteristically observed brain atrophy and physiological brain atrophy observed with aging.
- inhibittion means preventing or delaying the progression to a worse state
- inhibittion of brain atrophy means brain atrophy that progresses due to the neurodegenerative diseases described above, and aging. It refers to suppressing the physiological brain atrophy observed in
- improvement in the present disclosure means amelioration of symptoms or diseases, prevention or delay of exacerbation of symptoms or diseases, reversal, prevention or delay of progression of symptoms or diseases, treatment of symptoms or diseases, and the like.
- Immprovement in the present disclosure also includes the meaning of prevention.
- prevention means preventing or delaying the onset of symptoms or diseases in an application subject, or reducing the risk of developing symptoms or diseases in an application subject.
- INDUSTRIAL APPLICABILITY The composition of the present invention can suppress brain atrophy caused by loss of nerve cells in the neurodegenerative diseases described above, and can improve cognitive decline caused by such brain atrophy.
- the composition of the present invention can also suppress the physiological brain atrophy that appears or progresses with aging, and the deterioration of cognitive function caused by such physiological brain atrophy, for example, in healthy subjects. It can ameliorate the decline in memory, concentration, thinking ability, etc. observed with aging.
- the inventors of the present application have found that in those who have been diagnosed with MCI, the hippocampal and parahippocampal It was found that atrophy of brain regions including the gyrus and amygdala was suppressed, and cognitive functions such as orientation were improved.
- the cerebral atrophy-suppressing agent of the present disclosure is a cerebral atrophy-suppressing agent containing, as an active ingredient, a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175), which is administered to subjects diagnosed with mild cognitive impairment.
- the brain atrophy suppressing agent of the present disclosure contains a culture of Bifidobacterium breve, whose active ingredient resides mainly in the large intestine of infants. Therefore, the cerebral atrophy suppressing agent of the present disclosure is highly safe, has little need to worry about side effects even when administered continuously for a long period of time, and is very useful. Furthermore, the cerebral atrophy inhibitor of the present disclosure is highly safe even when used in combination with other drugs.
- the subject of administration of the agent for suppressing brain atrophy may be any healthy person, preferably a person judged to have mild cognitive impairment.
- subjects for administration of brain atrophy inhibitors are those who exhibit symptoms or disorders due to cognitive function decline, and healthy people who are required to prevent cognitive function decline, such as the elderly who are at risk of cognitive function decline and middle-aged and elderly people. It is preferable that the person is an elderly person, a middle-aged person, or the like.
- the method of the present disclosure can be applied to patients with neurodegenerative diseases known to exhibit brain atrophy such as Alzheimer's dementia, elderly people, middle-aged and middle-aged people who are likely to suffer from the neurodegenerative diseases, and It is preferably applied to elderly people who are likely to develop cerebral atrophy.
- a healthy subject means a person who does not have a specific chronic disease and who does not interfere with activities of daily living.
- MCI means a person whose main symptom is forgetfulness, but which hardly affects daily life and cannot be diagnosed as dementia.
- Mild cognitive impairment is the pre-dementia stage, considered to be an intermediate stage between healthy individuals and dementia patients, in which cognitive function declines more than expected in the normal aging process, but dementia A condition that is not diagnosed until There are three definitions of mild cognitive impairment: 1. 1. The person or family complains of deterioration in cognitive functions (memory, decision-making, reasoning, execution). 3. Cognitive function is not normal, but does not meet the diagnostic criteria for dementia. Minimal impairment in complex daily activities, but normal activities of daily living
- MCI includes, as an example, those diagnosed with MCI according to the diagnostic criteria for major neurocognitive disorder according to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5).
- the DSM-5 diagnostic criteria for dementia (2013) are as follows.
- A. Evidence of significant cognitive decline from previous performance levels in one or more cognitive domains (complex attention, executive functioning, learning and memory, language, perceptual-motor and social cognition) is based on : (1) the concept of having significant cognitive decline by the person, a familiar informant, or a clinician; Substantial impairment of cognitive performance as documented by quantified clinical assessments.
- D. The cognitive deficit is poorly explained by other psychiatric disorders (e.g. depression and schizophrenia)
- selection criteria Males and females aged 65 to 90 years at the time of informed consent Subjects who meet the objective evidence of a) to c) a) Complaints of memory impairment from the person or family b) Mini Mental State Examination (MMSE) score of 22 to 26 points c) Clinical Dementia scale (CDR, Clinical Dementia Rating 0.5 (suspected dementia) (3) Written informed consent has been obtained for participation in this study
- cerebral atrophy is performed by performing image analysis using MRI test data and comparing the volume of the cerebral cortex with that of a healthy subject.
- VSRAD registered trademark, Voxel-based Specific Regional analysis system for Alzheimer's Disease
- Pmod 3.7 image analysis software
- VSRAD is diagnostic support software for evaluating the degree of progression of Alzheimer's dementia using MRI test data, and can evaluate the degree of atrophy of the parahippocampal gyrus, hippocampus and amygdala.
- the parahippocampal gyrus, hippocampus and amygdala are sometimes referred to as VOI (Volume Of Interest). Atrophy of the VOI region is represented by a numerical value called "VOI atrophy”.
- Atrophy 0-1 Possibility of Alzheimer's dementia is low. 2) Degree of atrophy 1 to 2: If slight atrophy can be confirmed, future follow-up and subsequent MRI examination are required. 3) Degree of atrophy 2 to 3: When strong atrophy is observed, the possibility of developing Alzheimer's dementia increases. 4) When the degree of atrophy is 3 or more: It is almost certain that dementia has developed, and treatment for dementia is required. However, definitive diagnosis of dementia cannot be made by VSRAD alone.
- each VSRAD score Z score in VOI, percentage of whole brain atrophy area, percentage of atrophy area in VOI and atrophy
- At least one of the ratios (within VOI/whole brain) measured at the beginning of the study (also referred to as week 0) and at 24 weeks from the beginning of the study showed brain atrophy compared to the placebo group. If the group receiving inhibitors or the like is statistically significant, it is determined that brain atrophy is suppressed.
- the group ingesting a cerebral atrophy inhibitor or the like means a group ingesting at least one of cerebral atrophy inhibitor food and drink, cerebral atrophy-inhibiting food, cerebral atrophy-inhibiting supplement, and cerebral atrophy-inhibiting medicine.
- cognitive function is defined as ADAS-Jcog. (Alzheimer's Disease Assessment Scale-cognitive component-Japanese version).
- Cognitive function is evaluated by items, and the range of scores is 0 to 70 points. If all answers are correct, the score is 0, and if all the answers are incorrect, the score is 70. Therefore, the higher the score, the worse the cognitive function. It is often used as a standard test method in clinical trials for Alzheimer's disease.
- cognitive decline refers to a state in which the MMSE score is 22 or more and 26 or less and the CDR is 0.5.
- the improvement of cognitive function is judged according to the following criteria.
- word recall In the placebo group and the group that took brain atrophy inhibitors, etc., word recall, oral language ability, auditory comprehension of language, difficulty in expressing words in spontaneous speech, following verbal commands, finger and object naming, constructive acts, ideological movements, and orientation. , word recognition, and ability to recall test instructions.
- the group taking anti-atrophy drugs etc. is statistically significant, it is judged that the cognitive function is improved.
- the actual value measured at 24 weeks after the start of the survey was significantly higher than the actual value measured at the start of the survey for at least one of the above scores, whereas the group that took brain atrophy inhibitors, etc.
- the cognitive function is improved.
- the cognitive function is improved.
- statically significant means that the p value is ⁇ 0.05.
- Bifidobacterium breve is one of the fungal species belonging to the genus Bifidobacterium. Bifidobacterium breve mainly resides in the large intestine of infants. Bifidobacterium breve is an infant type Bifidobacterium genus together with Bifidobacterium longum subsp. known as bacteria. Bifidobacterium breve in this disclosure specifically refers to a particular strain numbered MCC1274 (FERM BP-11175).
- MCC1274 is an independent administrative agency National Institute of Advanced Industrial Science and Technology Patent Organism Depositary Center (1-1-1 Central 6, Higashi Tsukuba City, Ibaraki Prefecture 305-8566, Japan (now IPOD Independent Administrative Agency Product Evaluation Technology Institute Patent Organism Depositary Center ( NITE-IPOD): Deposited at Room 2-5-8120 Kazusa Kamatari, Kisarazu City, Chiba Prefecture 292-0818, Japan)) from August 25, 2009 under the deposit number of IPOD FERM BP-11175. .
- a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) can be easily obtained by, for example, culturing Bifidobacterium breve MCC1274 (FERM BP-11175).
- the culturing method is not particularly limited as long as these bacteria can grow, and culturing can be performed under appropriate conditions.
- the culture temperature is usually 25 to 50°C, preferably 35 to 42°C.
- Cultivation is preferably carried out under anaerobic conditions.
- culturing can be carried out while aerating anaerobic gas such as carbon dioxide gas.
- the medium for culturing Bifidobacterium breve MCC1274 (FERM BP-11175) used in the present disclosure is not particularly limited, and a medium commonly used for culturing bacteria belonging to the genus Bifidobacterium can be used. can.
- Nitrogen sources include, for example, ammonia, ammonium salts such as ammonium sulfate, ammonium chloride and ammonium nitrate, and nitrates.
- examples of inorganic salts that can be used include sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride and ferrous sulfate.
- Organic ingredients such as peptone, soybean flour, defatted soybean meal, meat extract and yeast extract may also be used.
- Bifidobacterium breve MCC1274 (FERM BP-11175) used in the present disclosure may be used as it is after culturing, or may be used after being diluted or concentrated. Bacteria may also be used.
- culture in the present disclosure is a concept including culture supernatant.
- the culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) contained as an active ingredient in the brain atrophy inhibitor of the present disclosure may be one or two or more.
- the cerebral atrophy suppressing agent of the present disclosure may consist of the active ingredient alone, or may be a composition in which the active ingredient and optional ingredients other than the active ingredient are blended.
- the optional ingredients are not particularly limited, and additives conventionally blended in pharmaceuticals (for example, formulation carriers described later) can be blended.
- Cultures containing Bifidobacterium breve MCC1274 were administered to healthy subjects, those diagnosed with mild cognitive impairment, those assessed as having cognitive decline, and subjects at risk of suffering from neurodegenerative diseases. can be provided for use in inhibiting brain atrophy of Cultures containing Bifidobacterium breve MCC1274 (FERM BP-11175) for use in inhibiting brain atrophy of the present disclosure can be used in healthy subjects, those diagnosed with mild cognitive impairment, and those with cognitive decline and neurodegenerative diseases.
- 1.0 ⁇ 10 6 to 1.0 ⁇ 10 12 CFU of Bifidobacterium breve MCC1274 (FERM BP-11175) per day is orally administered to a subject at risk of suffering from It is more preferably orally administered at 1.0 ⁇ 10 8 to 1.0 ⁇ 10 12 CFU, and more preferably orally administered at 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU. preferable.
- CFU represents a colony forming unit: Colony Forming Unit.
- Cultures containing Bifidobacterium breve MCC1274 (FERM BP-11175) were administered to healthy subjects, those diagnosed with mild cognitive impairment, those assessed as having cognitive decline, and subjects at risk of suffering from neurodegenerative diseases. It can be used for manufacturing a brain atrophy inhibitor for administration to.
- a brain atrophy inhibitor containing a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) of the present disclosure as an active ingredient was evaluated as a healthy subject, a person diagnosed with mild cognitive impairment, and cognitive decline.
- an effective amount of a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for suppressing brain atrophy is administered to a healthy subject who needs suppression of brain atrophy, and is diagnosed with mild cognitive impairment.
- the effective dose for suppressing brain atrophy is preferably 1.0 ⁇ 10 8 to 1.0 ⁇ 10 12 CFU, more preferably 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day. .
- the effective amount for suppressing brain atrophy is the content of Bifidobacterium breve MCC1274 (FERM BP-11175). Suppression of brain atrophy can prevent cerebrovascular disorders such as Alzheimer's disease, frontotemporal dementia, Lewy body disease, cerebral infarction and cerebral hemorrhage. Furthermore, the composition for suppressing cerebral atrophy of the present invention is also effective for healthy subjects, particularly from the viewpoint of pre-symptomatic disease countermeasures or preventive measures.
- Bifidobacterium breve for administration to subjects at risk of suffering from at least one of healthy subjects, subjects diagnosed with mild cognitive impairment, subjects assessed as having cognitive decline, and neurodegenerative diseases We will also provide a medicine for suppressing brain atrophy containing a culture containing MCC1274 (FERM BP-11175) as an active ingredient.
- the medicament of the present disclosure can be appropriately formulated into a desired dosage form suitable for oral administration.
- the dosage form is not particularly limited, for example, solid formulations such as powders, granules, tablets, troches and capsules; liquid formulations such as solutions, syrups, suspensions and emulsions, etc. can be formulated. .
- formulation can be suitably implemented by a well-known method according to a dosage form.
- the medicament of the present disclosure may be formulated by appropriately adding a pharmaceutical carrier.
- a pharmaceutical carrier In addition to cultures containing Bifidobacterium breve MCC1274 (FERM BP-11175), it is also possible to use ingredients such as excipients, pH adjusters, coloring agents and corrigents that are commonly used in formulations. can. Furthermore, it is also possible to use ingredients that have an effect of preventing, treating and/or ameliorating diseases or symptoms that are known or will be discovered in the future, depending on the intended purpose.
- various organic or inorganic carriers can be used depending on the dosage form.
- carriers for solid preparations include excipients, binders, disintegrants, lubricants, stabilizers and flavoring agents.
- excipient examples include sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin and carboxymethyl starch; crystalline cellulose and hydroxypropyl cellulose.
- cellulose derivatives such as , hydroxypropyl methylcellulose, carboxymethylcellulose and carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light silicic anhydride, synthetic aluminum silicate and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate.
- binder examples include gelatin; polyvinylpyrrolidone; and macrogol, in addition to the above excipients.
- disintegrant examples include, in addition to the excipients described above, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.
- lubricant examples include talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as Veegum and Geiro; boric acid; Acids; carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; mentioned.
- the stabilizer examples include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic anhydride;
- flavoring agents examples include sweeteners, acidulants, flavoring agents, and the like.
- carriers used include solvents such as water and flavoring agents.
- the content of the culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) in the medicament of the present disclosure is not particularly limited, but the daily dosage for an effective brain atrophy inhibitory effect can be reasonably adjusted. It preferably contains a culture containing an ingestible amount of Bifidobacterium breve MCC1274 (FERM BP-11175), wherein Bifidobacterium breve MCC1274 (FERM BP-11175) is between 1.0 ⁇ 10 6 and 1 0 ⁇ 10 12 CFU/g, more preferably 1.0 ⁇ 10 8 to 1.0 ⁇ 10 12 CFU/g, more preferably 1.0 ⁇ 10 9 to 1.0 It is particularly preferable to contain x10 11 CFU/g.
- the daily dosage of the culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) in the medicament of the present disclosure is at least 1.0 ⁇ 10 6 CFU/g or more, preferably 1.0 ⁇ 10 6 to 1.0 ⁇ 10 12 CFU/g, more preferably 1.0 ⁇ 10 8 to 1.0 ⁇ More preferably 10 12 CFU/g, particularly preferably 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU/g.
- the medicament of the present disclosure may be administered orally in 1 to 3 divided doses per day.
- Subjects for administration are usually humans, but the present disclosure also includes mammals other than humans, such as companion animals such as dogs and cats, and farm animals such as cattle, sheep and pigs.
- Bifidobacterium breve FERM BP-11175 which displays brain atrophy inhibitory effects in healthy subjects, subjects diagnosed with mild cognitive impairment, subjects evaluated as having cognitive decline, and subjects at risk of suffering from neurodegenerative diseases.
- Bifidobacterium breve FERM BP-11175 culture containing Bifidobacterium breve FERM BP-11175 is also provided.
- Foods and beverages regardless of the form such as liquid, paste, solid or powder, in addition to tablet confectionery, liquid food and feed (including pets), for example, wheat flour products, instant foods, processed agricultural products , processed marine products, processed livestock products, milk and dairy products, fats and oils, basic seasonings, compound seasonings/foods, frozen foods, confectionery, beverages and other commercially available foods.
- dairy products include fermented milk, milk drinks, lactic acid bacteria drinks, sweetened condensed milk, skimmed milk powder, sweetened milk powder, modified milk powder, cream, cheese, butter and ice creams.
- Wheat flour products include, for example, bread, macaroni, spaghetti, noodles, cake mixes, fried chicken flour and bread crumbs.
- instant foods include instant noodles, cup noodles, retort/cooked foods, cooked canned foods, microwave oven foods, instant soups/stews, instant miso soups/soups, canned soups, freeze-dried foods, and other instant foods. be done.
- processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, and cereals (processed grain products).
- processed marine products include canned marine products, fish hams and sausages, fish paste products, marine delicacies, and tsukudani.
- processed livestock products include canned livestock products, pastes, and livestock hams and sausages.
- Fats and oils include, for example, butter, margarines and vegetable oils.
- Basic seasonings include, for example, soy sauce, miso, sauces, processed tomato seasonings, mirin, and vinegar. Examples include dressings, noodle soups, spices and other complex seasonings.
- Frozen foods include, for example, material frozen foods, half-cooked frozen foods, and cooked frozen foods.
- Confectionery includes, for example, caramels, candies, chewing gums, chocolates, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confections, rice confections, bean confections, dessert confections and other confectionery.
- beverages include carbonated drinks, natural fruit juices, fruit juice drinks, soft drinks containing fruit juice, pulp drinks, fruit drinks containing fruit, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, and concentrated drinks.
- sports drinks, nutritional drinks, alcoholic beverages and other beverages of choice Commercially available foods other than those described above include, for example, baby food, furikake and ochazuke seaweed.
- dairy products are particularly preferable, and fermented milk is particularly preferable.
- fermented milk is particularly preferable.
- the food, drink, food, and supplements provided by the present invention can be used in the same manner as the pharmaceuticals described in ⁇ Pharmaceuticals> above, and can also be used to the extent that the suppression of brain atrophy is not intended. That is, when the Bifidobacterium breve MCC1274 (FERM BP-11175) contained in the food, food, and supplements according to the present invention is used as a standard, the Bifidobacterium breve MCC1274 ( FERM BP-11175) can be applied to the target of the drug so that the amount used is the same as the amount of Bifidobacterium breve MCC1274 (FERM BP-11175) contained in the drug.
- the Bifidobacterium breve MCC1274 FERM BP-11175
- the food, drink, food and supplement according to the present invention are used in subjects (e.g., humans or other mammals) who do not have "pathological" or "abnormal” symptoms, conditions or diseases, i.e., applied to a subject (e.g., a human or other mammal) in a "healthy” or “normal” condition to maintain or enhance the "healthy” or “normal” condition. can do. Furthermore, it is applied to maintain or enhance a "healthy" or "normal” state for "healthy subjects concerned about brain atrophy” or "healthy subjects concerned about cognitive decline". can do.
- subjects e.g., humans or other mammals
- a subject e.g., a human or other mammal
- it is applied to maintain or enhance a "healthy” or "normal” state for "healthy subjects concerned about brain atrophy” or "healthy subjects concerned about cognitive decline". can do.
- the culture containing said Bifidobacterium breve MCC1274 (FERM BP-11175) is a component of a pharmaceutical composition or a component of a food composition
- said Bifidobacterium breve Since the pharmacological effect of the culture itself containing MCC1274 (FERM BP-11175) is basically the same, the amount and method of application of the food composition may vary depending on the desired effect of the Bifidobacterium.
- a culture containing Breve MCC1274 (FERM BP-11175) can be used as a reference and adjusted as appropriate.
- Subjects e.g., humans or other mammals
- that do not have an "pathological" or "abnormal” symptom, condition or disease i.e., subjects that are in a "healthy” or “normal” Other mammals
- foods, drinks, foods and supplements that are applied to maintain or improve the "healthy” or “normal” condition may be particularly referred to as “functional foods” .
- the act of "displaying” includes all acts for informing consumers of the use of brain atrophy suppression, and any expression that can remind or infer the use of the display. Regardless of the purpose, the content of the display, the object or medium to be displayed, etc., all of them fall under the "display" act of this disclosure.
- the "indication" be expressed in such a way that consumers can directly recognize the above usage.
- the content of the display is a display approved by the government (for example, a display that is approved based on various systems established by the government and performed in a manner based on such approval).
- a display that is approved based on various systems established by the government and performed in a manner based on such approval.
- labeling includes health food, functional food, food for the sick, enteral nutritional food, food for special dietary uses, food with health claims, food for specified health use, food with function claims, food with nutrient function claims, and medical parts. Display as an off-the-shelf product is also possible.
- labeling approved by the Consumer Affairs Agency for example, labeling approved by the Foods for Specified Health Uses System, the Foods with Function Claims System, and similar systems can be mentioned. More specifically, labeling as a food for specified health use, labeling as a food for specified health use with certain conditions, labeling as a food with function claims, labeling to the effect that it affects the structure and function of the body, labeling to reduce the risk of disease, etc.
- a typical example is labeling as a food for specified health use (especially, labeling of health use) specified in the Ordinance for Enforcement of the Health Promotion Law (Ministry of Health, Labor and Welfare Ordinance No. 86 of April 30, 2003). ), labeling as food with function claims stipulated in the Food Labeling Law (Law No. 70 of 2013) and similar labeling.
- the wording used to perform the above-mentioned labeling is not limited to words such as "for suppressing brain atrophy, for preventing brain atrophy", and other words may also be used to prevent brain atrophy.
- any term that expresses the effect of prevention, amelioration and/or treatment of various diseases or symptoms related to suppression is encompassed within the scope of the present disclosure. Such terms include, for example, the improvement of brain atrophy, the prevention of brain atrophy, the prevention of brain atrophy, the improvement of cognitive function, the improvement and improvement of cognitive function, orientation, and recognition of the effects of support for consumers. It is also possible to display based on various applications such as
- Placebo-controlled randomized controlled trial (RCT, Randomized Controlled Trial) ⁇ Target> A total of 130 outpatients who met all of the following selection criteria and who did not meet any of the following exclusion criteria among outpatients who received medical care at Juntendo Tokyo Koto Geriatric Medical Center attached to Juntendo University School of Medicine were targeted.
- Table 1 shows the ingredients of the test foods used in the intervention.
- Bifidobacterium intake group Powder (stick), Bifidobacterium 20 billion/stick (2.0 g/day)
- Placebo group Powder (stick), Bifidobacterium billion / stick (2.0 g / day) Intervention period: 24 weeks
- ADAS-Jcog. The ADAS-Jcog. Table 2 shows the measured values and variation values (at 24 weeks-at 0 weeks).
- VSRAD head MRI FAS analysis of head MRI (VSRAD), which is a secondary endpoint, was performed on 89 subjects (42 in the bifidobacterium intake group, 47 in the placebo intake group). Table 3 shows the measured values and variation values (at 24 weeks-0 week).
- Table 4 shows the results of subgroup analysis based on the Z-score within the VOI at week 0.
- Figure 1 shows the results showing the variation of the VSRAD score in each subject
- Figure 2 shows representative MRI images.
- VSRAD the brain region where specific atrophy is observed in dementia such as Alzheimer's disease is set as VOI, and compared with the standardized brain capacity data of 80 healthy adults aged 54 to 86, the subject's brain Atrophy degree can be evaluated. Therefore, by ingesting bifidobacteria from this data, the ratio of the whole brain atrophy area improved in the FAS analysis, and a subgroup targeted for those who originally had progressed VOI atrophy (Z score in VOI is 1 or more) The analysis revealed that the intra-VOI Z-score, the percentage of whole brain atrophic area, and the percentage of atrophic area within the VOI were all improved.
- a brain capable of suppressing the progression of brain atrophy in any subject selected from a subject diagnosed with mild cognitive impairment and a subject at risk of suffering from at least one of cognitive decline and neurodegenerative disease
- An atrophy inhibitor can be provided.
- the brain atrophy suppressing agent of the present disclosure is a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) as an active ingredient, so it is excellent in safety and there is no concern about side effects even if it is administered continuously for a long period of time. It is very useful because it is less necessary.
- This disclosure includes, but is not limited to: [1] Bifidobacterium breve MCC1274 administered to any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject evaluated as having cognitive decline, and a subject at risk of suffering from a neurodegenerative disease
- a brain atrophy inhibitor comprising a culture containing (FERM BP-11175) as an active ingredient.
- the brain atrophy inhibitor is orally administered to the subject such that Bifidobacterium breve MCC1274 (FERM BP-11175) is 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day.
- the agent for suppressing brain atrophy according to [1], comprising the culture in an amount of [3] The brain atrophy inhibitor according to [1] or [2], wherein the subject has been diagnosed with mild cognitive impairment.
- the effective amount of culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for suppressing brain atrophy was evaluated in healthy subjects requiring suppression of brain atrophy, those diagnosed with mild cognitive impairment, and those with cognitive decline.
- a method for suppressing cerebral atrophy comprising administration to any subject selected from subjects who are at risk of suffering from neurodegenerative diseases.
- An effective amount of a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for suppressing brain atrophy was administered to healthy subjects requiring suppression of brain atrophy, subjects diagnosed with mild cognitive impairment, cognitive decline, and neurodegenerative diseases.
- a method for suppressing non-therapeutic brain atrophy comprising administering to any subject selected from subjects at risk of suffering from [6]
- the brain atrophy-suppressing effective amount is an amount such that 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU of Bifidobacterium breve MCC1274 (FERM BP-11175) is orally administered to the subject per day.
- the method for suppressing brain atrophy according to [4] or [5], wherein [7] The method for suppressing brain atrophy according to any one of [4] to [6], wherein the subject has been diagnosed with mild cognitive impairment.
- [8] Use in suppressing brain atrophy in any subject selected from healthy subjects, subjects diagnosed with mild cognitive impairment, subjects evaluated to have cognitive decline, and subjects at risk of suffering from neurodegenerative diseases
- the culture contains bifido in an amount such that 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU of Bifidobacterium breve MCC1274 (FERM BP-11175) is orally administered to the subject per day.
- a brain atrophy inhibitor administered to any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject evaluated as cognitively impaired, and a subject at risk of suffering from a neurodegenerative disease Use of a culture comprising Bifidobacterium breve MCC1274 (FERM BP-11175) for the production of [11]
- the amount of the brain atrophy inhibitor is orally administered to the subject at 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU of Bifidobacterium breve MCC1274 (FERM BP-11175) per day.
- the brain atrophy inhibitor of [13] wherein the subject has been diagnosed with mild cognitive impairment.
- a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) was evaluated as an effective amount for suppressing brain atrophy in healthy subjects requiring suppression of brain atrophy, those diagnosed with mild cognitive impairment, and those with cognitive decline.
- Bifidobacterium breve MCC1274 (FERM BP-11175) 1.0 ⁇ 10 6 to 1.0 ⁇ 10 12 per day in any subject selected from subjects at risk of suffering from neurodegenerative disease
- a method for suppressing brain atrophy comprising orally administering CFU.
- Bifidobacterium breve MCC1274 As an effective amount for suppressing brain atrophy of culture containing Bifidobacterium breve MCC1274 (FERM BP-11175), healthy subjects requiring suppression of brain atrophy, subjects diagnosed with mild cognitive impairment, and cognitive impairment were evaluated.
- Bifidobacterium breve MCC1274 (FERM BP-11175) 1.0 ⁇ 10 6 to 1.0 ⁇ 10 12 per day in any subject selected from subjects at risk of suffering from neurodegenerative disease
- a non-therapeutic method for suppressing brain atrophy comprising orally administering CFU.
- a culture containing an amount of Bifidobacterium breve MCC1274 (FERM BP-11175).
- Bifidobacterium breve MCC1274 (FERM BP-11175).
- the amount of the food and drink ingested by the subject is such that Bifidobacterium breve MCC1274 (FERM BP-11175) is 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day.
- the food or drink according to [20] comprising the culture.
- a food for suppressing brain atrophy containing a culture containing (FERM BP-11175) as an active ingredient is ingested by the subject so that Bifidobacterium breve MCC1274 (FERM BP-11175) is 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day.
- Bifidobacterium breve for intake by any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject evaluated as having cognitive decline, and a subject at risk of suffering from a neurodegenerative disease A supplement for suppressing brain atrophy containing a culture containing MCC1274 (FERM BP-11175) as an active ingredient.
- the supplement for suppressing brain atrophy is taken by the subject so that Bifidobacterium breve MCC1274 (FERM BP-11175) is 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day.
- Bifidobacterium breve for administration to any subject selected from a healthy subject, a subject diagnosed with mild cognitive impairment, a subject assessed as having cognitive decline, and a subject at risk of suffering from a neurodegenerative disease A medicament for suppressing brain atrophy containing a culture containing MCC1274 (FERM BP-11175) as an active ingredient.
- the drug for suppressing brain atrophy is orally administered to the subject so that Bifidobacterium breve MCC1274 (FERM BP-11175) is 1.0 ⁇ 10 9 to 1.0 ⁇ 10 11 CFU per day.
- the medicament for suppressing cerebral atrophy according to [29] comprising the culture in an amount of [31]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本願は、2021年10月22日に日本に出願された特願2021-173451号について優先権を主張し、その内容をここに援用する。
アルツハイマー病は、認知症の50%~60%を占める神経変性疾患である。このアルツハイマー病の神経病理学的特徴は、大脳皮質や海馬での神経原線維変性、老人斑及び大量の神経細胞脱落である。神経原線維変性は、微小管結合タンパクの1つであるタウタンパクが過剰にリン酸化され線維封入体となったものである。老人斑は、アミロイドβタンパクの細胞外蓄積である。アルツハイマー病では、このアミロイドβタンパクの蓄積が神経原線維変性を加速し、繊維化したタウタンパクは、細胞内輸送を阻害する。さらには、アミロイドβタンパク自体がシナプスの機能障害などの細胞毒性を有する。
今後、超高齢者社会の到来とともに、認知症患者が激増し、社会的な問題となることが懸念される。そこで、現在、特に、食事など生活習慣への介入によって、アルツハイマー病等の認知症の発症予防、改善及び進行抑制についての研究が求められている。
高齢者の4人に1人は、軽度認知障害(MCIともいう,Mild Cognitive Impairment)もしくは認知症であるといわれている。MCIは、認知症の手前の状態である。MCIは、認知症のように普段の生活に支障をきたすほどではないが、記憶などの能力が低下し、健常者と認知症の境界域だと言われている。MCIと診断された者の約半数は、5年以内にアルツハイマー型認知症に移行するといわれている。
本開示の別の態様は、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与することを含む脳萎縮の抑制方法の提供である。
本開示のまた別の態様は、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象の脳萎縮の抑制における使用のためのBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の提供である。
本開示のさらに別の態様は、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される脳萎縮抑制剤を製造するための、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の使用の提供である。
なお、ここに記載された効果は、必ずしも限定されるものではなく、本明細書中に記載されたいずれかの効果であってもよい。
本開示における「抑制」とは、より悪い状態への進行を妨げる又は遅らせることを意味し、「脳萎縮の抑制」とは、上記した神経変性疾患により進行する脳の委縮や、加齢に伴って観察される生理的な脳萎縮を抑制することをいう。
また、本開示における「改善」とは、症状又は疾患の好転、症状又は疾患の悪化の防止若しくは遅延、症状又は疾患の進行の逆転、防止若しくは遅延、又は症状又は疾患の治療等を意味する。本開示における「改善」とは、予防の意味をも包含する。
本開示における「予防」とは、適用対象における症状又は疾患の発症の防止若しくは発症の遅延、又は適用対象における症状又は疾患の発症の危険性を低下させる等を意味する。
本発明の組成物は、上記した神経変性疾患において、神経細胞の脱落により生じる脳萎縮を抑制することができ、かかる脳萎縮に起因する認知機能の低下を改善することができる。また、本発明の組成物は、加齢に伴って出現又は進行する生理的な脳萎縮をも抑制することができ、かかる生理的な脳萎縮に起因する認知機能の低下、たとえば、健常者において加齢に伴って観察される記憶力の低下、集中力の低下及び思考力の低下等を改善することができる。
本開示の脳萎縮抑制剤は、軽度認知障害と診断された対象に投与される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制剤である。
本開示の脳萎縮抑制剤は、その有効成分が、主に乳幼児の大腸内に多く住みついている、ビフィドバクテリウム・ブレーベの培養物である。よって、本開示の脳萎縮抑制剤は、安全性に優れ、長期間、連続的に投与しても副作用を心配する必要性も少なく、非常に有用である。さらに、本開示の脳萎縮抑制剤は、他の薬剤との併用においても安全性が高い。
さらにまた、本開示の方法は、アルツハイマー型認知症等の脳萎縮を呈することが知られている神経変性疾患の患者や、前記神経変性疾患に罹患するおそれのある高齢者や中・壮年者及び脳萎縮を呈するおそれのある高齢者等に、好適に適用される。
本開示において、MCIとは物忘れが主たる症状だが、日常生活への影響はほとんどなく、認知症とは診断できない状態である者を意味する。
軽度認知障害とは、認知症の前段階に当たり、健常者と認知症患者との中間の段階と考えられ、正常な老化過程で予想されるよりも認知機能が低下しているが、認知症とまでは診断されない状態をいう。
軽度認知障害の定義として、下記の3つが挙げられる。
1.本人または家族が認知機能(記憶力、決定力、理由づけ、実行力)の低下を訴えている
2.認知機能は正常ではないが、認知症の診断基準を満たさない
3.複雑な日常動作に最低限の障害はあるが、日常生活は普通に過ごせる
A.1つ以上の認知領域(複雑性注意、遂行機能、学習および記憶、言語、知覚-運動及び社会的認知)において、以前の行為水準から有意な認知の低下があるという証拠が以下に基づいている:
(1)本人、本人をよく知る情報提供者、または臨床家による、有意な認知機能の低下があったという概念、及び
(2)標準化された神経心理学的検査によって、それがなければ他の定量化された臨床的評価によって記録された、実質的な認知行為の障害
B.毎日の活動において、認知欠損が自立を阻害する(すなわち、最低限、請求書を支払う、及び内服薬を管理するなどの、複雑な手段的日常生活動作に援助を必要とする)
C.その認知欠損は、せん妄の状況でのみ起こるものではない
D.その認知欠損は、他の精神疾患によってうまく説明されない(例:うつ病及び統合失調症)
(選択基準)
(1)同意取得時年齢が65歳以上90歳未満の男女
(2)DSM-5(精神障害の診断・統計マニュアル第5版、2013年、アメリカ精神医学会)のMCIと診断され、以下のa)~c)の客観的証拠を満たす者
a)本人又は家族から記憶障害の訴えがある
b)ミニメンタルステート検査(MMSE,Mini Mental State Examination)スコアが22点以上26点以下
c)臨床的認知症尺度(CDR,Clinical Dementia Ratingが0.5(認知症の疑い)
(3)本試験への参加について書面によるインフォームド・コンセントが得られている
パーキンソン病、ハンチントン病、正常圧水頭症、進行性核上性麻痺、てんかん、多発性硬化症、頭蓋内感染症又は後遺症を残した頭部外傷がある場合。
大うつ病や双極性障害、又はアルコールや他の薬物依存の既往がある場合。多発脳梗塞、脳腫瘍又は硬膜下血腫が認められた場合。
ビタミンB12・葉酸欠乏による認知機能障害の場合。
神経梅毒の場合。
甲状腺機能異常による認知機能障害の場合。
重篤な脳血管疾患、心疾患、肝疾患、腎疾患、消化器疾患、内分泌代謝疾患又は届出が必要な感染症などに罹患している者。
消化器系のがんの既往歴のある者、又はその疾患のために現在治療、投薬を受けている者。
胃切除、胃腸縫合術又は腸管切除など消化器系に大きな手術歴のある者。炎症性腸症候群等の消化器障害を有する者。
便通に影響を与える医薬品(抗生物質、整腸剤、便秘薬及び下痢止め)や健康食品・サプリメント(乳酸菌、ビフィズス菌、オリゴ糖及び食物繊維など)を常用している者。
血圧測定又は血液検査で著しい異常が認められる者。
高度の貧血のある者。
薬物又は食品に対しアレルギー症状を示す恐れのある者。
過度の喫煙及びアルコールの常用者並びに食事、睡眠などの生活習慣が極度に不規則な者。
抗認知症薬、向精神薬(抗うつ剤及び抗精神病薬等)を服用している場合。重度の糖尿病を有し、インスリンを投与している場合。
ペースメーカー、動脈瘤クリップ、人工弁、人工内耳その他磁性体・電気伝導性の金属が入っており、脳MRI撮像時に問題が生じる場合。
新規アルツハイマー型認知症治療薬の治験に参加している又は参加を予定しており、本治験と両方に参加する可能性がある場合。また、他の臨床試験に現在参加しているか、あるいは1ヶ月以内に参加していた者。
その他、治験責任医師が不適格と認定した場合。
例えば、VSRAD(登録商標、Voxel-based Specific Regional analysis system for Alzheimer’s Disease)(エーザイ社製 https://medical.eisai.jp/products/vsrad/)や画像解析ソフト「Pmod3.7」(ピーモッドテクノロジーズ社(Pmod Technologies Ltd.))を用いてMRI(Magnetic Resonance Imaging)画像を解析することによって評価が行われる。
VOI領域の萎縮は、「VOI萎縮度」という数値で表される。(松田博史,“III 画像統計ソフトを知る-入手方法,特徴,有用性,課題 1.VSRAD-DARTELを含む”,月刊インナービジョン,株式会社インナービジョン,2010年12月25日,第26巻,第1号,p.29-32を参照)
1)萎縮度0~1:アルツハイマー型認知症の可能性は低い。
2)萎縮度1~2:若干の萎縮が確認できる場合、今後の経過観察と引き続きMRI検査が必要となる。
3)萎縮度2~3:強い萎縮がみられる場合、アルツハイマー型認知症を発症している可能性が高まる。
4)萎縮度3以上の場合:ほぼ確実に認知症を発症しているとみられ、認知症の治療が必要となる。
ただし、VSRADのみによって認知症の確定診断はできない。
ADAS-Jcog.は、単語再生、口頭言語能力、言語の聴覚的理解、自発話における喚語困難、口頭命令に従う、手指及び物品呼称、構成行為、観念運動、見当識、単語再認、及びテスト教示の再生能力の11項目によって認知機能を評価し、得点の範囲は0~70点である。すべて正解すると0点、すべて不正解であると70点となるため、得点が高いほど認知機能は不良なことを意味する。アルツハイマー病の治験では標準的な検査法として用いられることが多い。
本開示におけるビフィドバクテリウム・ブレーベは、特に、MCC1274(FERM BP-11175)という番号が付された特定の菌株を指す。MCC1274は、独立行政法人産業技術総合研究所特許生物寄託センター(日本国〒305-8566茨城県つくば市東1-1-1中央第6(現IPOD独立行政法人製品評価技術基盤機構特許生物寄託センター(NITE-IPOD):日本国〒292-0818千葉県木更津市かずさ鎌足2-5-8120号室)))に、2009年8月25日より、IPOD FERM BP-11175の受託番号で寄託されている。
本開示の脳萎縮の抑制における使用のためのビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)を含む培養物は、健常者、軽度認知障害と診断された者及び認知機能低下と神経変性疾患に罹患する恐れがある対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×106~1.0×1012CFUとなるよう経口投与されることが好ましく、1.0×108~1.0×1012CFUとなるよう経口投与されることがより好ましく、1.0×109~1.0×1011CFUとなるよう経口投与されることがさらに好ましい。
なお、CFUは、コロニー形成単位:Colony Forming Unitを表す。
本開示の脳萎縮の抑制方法は、ビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象に1日あたり1.0×106~1.0×1012CFUを経口投与することを含む。脳萎縮抑制有効量は、1日あたり1.0×108~1.0×1012CFUであることが好ましく、1.0×109~1.0×1011CFUであることがより好ましい。ここで、脳萎縮抑制有効量とは、ビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)の含有量である。
なお、脳萎縮の抑制により、アルツハイマー病、前頭側頭型認知症、レビー小体病、脳梗塞及び脳出血等の脳血管障害を予防することが可能である。さらに、本発明の脳萎縮抑制用組成物は、健常な対象者に対しても、特に、未病対策、又は、予防的な観点から有効である。
本開示では、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患の少なくとも一方に罹患する恐れがある対象に投与するための、ビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用医薬の提供も行う。
なお、経口投与用の液剤の場合に使用する担体としては、水等の溶剤及び矯味矯臭剤等が挙げられる。
本開示では、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象における脳萎縮抑制効果を表示した、Bifidobacterium breve FERM BP-11175を含む培養物を含む飲食品、及び、軽度認知障害と診断された対象に摂取される、Bifidobacterium breve FERM BP-11175を含む培養物を有効成分とするサプリメントの提供も行われる。
小麦粉製品としては、例えば、パン、マカロニ、スパゲッティ、めん類、ケーキミックス、から揚げ粉及びパン粉等が挙げられる。
即席食品類としては、例えば、即席めん、カップめん、レトルト・調理食品、調理缶詰め、電子レンジ食品、即席スープ・シチュー、即席みそ汁・吸い物、スープ缶詰め、フリーズ・ドライ食品及びその他の即席食品等が挙げられる。
農産加工品としては、例えば、農産缶詰め、果実缶詰め、ジャム・マーマレード類、漬物、煮豆類、農産乾物類及びシリアル(穀物加工品)等が挙げられる。
水産加工品としては、例えば、水産缶詰め、魚肉ハム・ソーセージ、水産練り製品、水産珍味類及びつくだ煮類等が挙げられる。
畜産加工品としては、例えば、畜産缶詰め・ペースト類及び畜肉ハム・ソーセージ等が挙げられる。
油脂類としては、例えば、バター、マーガリン類及び植物油等が挙げられる。
基礎調味料としては、例えば、しょうゆ、みそ、ソース類、トマト加工調味料、みりん類及び食酢類等が挙げられ、前記複合調味料・食品類として、調理ミックス、カレーの素類、たれ類、ドレッシング類、めんつゆ類、スパイス類及びその他の複合調味料等が挙げられる。
冷凍食品としては、例えば、素材冷凍食品、半調理冷凍食品及び調理済冷凍食品等が挙げられる。
菓子類としては、例えば、キャラメル、キャンディー、チューインガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、米菓子、豆菓子、デザート菓子及びその他の菓子等が挙げられる。
飲料類としては、例えば、炭酸飲料、天然果汁、果汁飲料、果汁入り清涼飲料、果肉飲料、果粒入り果実飲料、野菜系飲料、豆乳、豆乳飲料、コーヒー飲料、お茶飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料及びその他の嗜好飲料等が挙げられる。
前記以外の市販食品としては、例えば、ベビーフード、ふりかけ及びお茶漬けのり等が挙げられる。
「病的な」又は「異常な」症状、状態又は疾患を有しない対象(例えば、ヒト又はその他の哺乳動物)、すなわち、「健常な」又は「正常な」状態にある対象(例えば、ヒト又はその他の哺乳動物)に対して、「健常な」又は「正常な」状態を維持するため、又は増進するために適用する飲食品、食品及びサプリメントを、特に「機能性食品」と称する場合がある。
MCIと診断された者を対象としたBifidobacterium breve MCC1274(FERM BP-11175)(以下、単に「ビフィズス菌」とも称する。)摂取による脳萎縮の抑制及び認知機能の改善に関する試験。
<対象>
順天堂大学医学部附属順天堂東京江東高齢者医療センターなどを受診した外来診療受診者のうち、以下の選択基準をすべて満たし、かつ、以下の除外基準のいずれにも該当しない者130名を対象とした。
(1)同意取得時年齢が65歳以上90歳未満の男女
(2)DSM-5(精神障害の診断・統計マニュアル第5版、2013年、アメリカ精神医学会)の=MCIと診断され、以下のa)~c)の客観的証拠を満たす者
a)本人又は家族から記憶障害の訴えがある
b)ミニメンタルステート検査(MMSE,Mini Mental State Examination)スコアが22点以上26点以下
c)臨床的認知症尺度(CDR,Clinical Dementia Ratingが0.5(認知症の疑い)
(3)本試験への参加について書面によるインフォームド・コンセントが得られている
パーキンソン病、ハンチントン病、正常圧水頭症、進行性核上性麻痺、てんかん、多発性硬化症、頭蓋内感染症又は後遺症を残した頭部外傷がある場合。
大うつ病や双極性障害又はアルコールや他の薬物依存の既往がある場合。多発脳梗塞、脳腫瘍又は硬膜下血腫が認められた場合。
ビタミンB12・葉酸欠乏による認知機能障害の場合。
神経梅毒の場合。
甲状腺機能異常による認知機能障害の場合。
重篤な脳血管疾患、心疾患、肝疾患、腎疾患、消化器疾患、内分泌代謝疾患又は届出が必要な感染症などに罹患している者。
消化器系のがんの既往歴のある者、又はその疾患のために現在治療、投薬を受けている者。
胃切除、胃腸縫合術又は腸管切除など消化器系に大きな手術歴のある者。炎症性腸症候群等の消化器障害を有する者。
便通に影響を与える医薬品(抗生物質、整腸剤、便秘薬及び下痢止め)や健康食品・サプリメント(乳酸菌、ビフィズス菌、オリゴ糖及び食物繊維など)を常用している者。
血圧測定又は血液検査で著しい異常が認められる者。
高度の貧血のある者。
薬物又は食品に対しアレルギー症状を示す恐れのある者。
過度の喫煙及びアルコールの常用者並びに食事、睡眠などの生活習慣が極度に不規則な者。
抗認知症薬、向精神薬(抗うつ剤及び抗精神病薬等)を服用している場合。重度の糖尿病を有し、インスリンを投与している場合。
ペースメーカー、動脈瘤クリップ、人工弁、人工内耳その他磁性体・電気伝導性の金属が入っており、脳MRI撮像時に問題が生じる場合。
新規アルツハイマー型認知症治療薬の治験に参加している又は参加を予定しており、本治験と両方に参加する可能性がある場合。また、他の臨床試験に現在参加しているか、あるいは1ヶ月以内に参加していた者。
その他、治験責任医師が不適格と認定した場合。
表1に、介入に使用した試験食品の含有成分を示す。
ビフィズス菌摂取群:
粉末(スティック)・ビフィズス菌 200億/スティック(2.0g/日)
プラセボ摂取群:
粉末(スティック)・ビフィズス菌 0億/スティック(2.0g/日)
介入期間:24週間
(主要評価項目)
ADAS-Jcog.(Alzheimer’s Disease Assessment Scale-cognitive component-Japanese version)
頭部MRI(VSRAD: voxel-based specific regional analysis system for Alzheimer’s Disease)
115人を対象としたFAS(Full Analysis Set)解析(ビフィズス菌摂取群55名、プラセボ摂取群60名)における主要評価項目であるADAS-Jcog.の実測値及び変動値(24週時点-0週時点)を表2に示す。
表2より、プラセボ摂取群と比較してビフィズス菌摂取群では認知機能の一部である見当識が有意に改善したことがわかる。
副次評価項目である頭部MRI(VSRAD)のFAS解析は、89名(ビフィズス菌摂取群42名、プラセボ摂取群47名)が対象となった。
表3に、各VSRADスコア(VOI内のZスコア、全脳萎縮領域の割合、VOI内萎縮領域の割合及び萎縮比(VOI内/全脳))の実測値及び変動値(24週時点-0週時点)を示す。
VOI,Volume Of Interest
Bifidobacterium breve MCC1274(FERM BP-11175)を1日あたり2.0g(200億個)ずつ24週間摂取したことで、全脳萎縮領域の割合が改善するだけでなく、特に認知症で萎縮が認められる海馬、海馬傍回及び扁桃を含むVOI領域の脳萎縮が改善していた。
また、神経心理学的検査では見当識の改善が認められた。見当識とは、日時、場所及び周りの人物など自分の置かれた状況を判断する能力であり、海馬を始めとする複数の脳領域が機能を担うことが知られている。また、見当識は、MCIから認知症への移行を評価する上で感度が非常に高い認知領域であることが知られている。そのため、Bifidobacterium breve MCC1274(FERM BP-11175)は、脳萎縮を抑制することで、見当識などの認知機能の低下を抑制することが示唆された。
[1] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制剤。
[2] 前記脳萎縮抑制剤が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×109~1.0×1011CFUとなるよう経口投与される量の前記培養物を含む、[1]に記載の脳萎縮抑制剤。
[3] 前記対象が軽度認知障害と診断されたものである、[1]又は[2]に記載の脳萎縮抑制剤。
[4] Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与することを含む脳萎縮の抑制方法。
[5] Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下、神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与することを含む非治療的脳萎縮の抑制方法。
[6] 前記脳萎縮抑制有効量が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)1.0×109~1.0×1011CFUが経口投与される量である、[4]又は[5]に記載の脳萎縮の抑制方法。
[7] 前記対象が軽度認知障害と診断されたものである、[4]~[6]の何れか1項に記載の脳萎縮の抑制方法。
[8] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象の脳萎縮の抑制における使用のためのBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物。
[9] 前記培養物が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)1.0×109~1.0×1011CFUが経口投与される量のビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)を含む、[8]に記載の培養物。
[10] 前記対象が軽度認知障害と診断されたものである、[8]又は[9]に記載の培養物。
[11] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される脳萎縮抑制剤を製造するための、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の使用。
[11] 前記脳萎縮抑制剤が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)1.0×109~1.0×1011CFUが経口投与される量のビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)を含む、[10]に記載のBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の使用。
[12] 前記対象が軽度認知障害と診断されたものである、[10]又は[11]に記載のBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の使用。
[13] Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制剤であって、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×106~1.0×1012CFUを経口投与される量のBifidobacterium breve MCC1274(FERM BP-11175)を含む脳萎縮抑制剤。
[14] 前記対象が軽度認知障害と診断されたものである、[13]に記載の脳萎縮抑制剤。
[15] Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量として、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)1.0×106~1.0×1012CFUを経口投与することを含む脳萎縮の抑制方法。
[16] Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量として、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)1.0×106~1.0×1012CFUを経口投与することを含む非治療的脳萎縮の抑制方法。
[17] 前記対象が軽度認知障害と診断されたものである、[15]又は[16]に記載の脳萎縮の抑制方法。
[18] 脳萎縮の抑制における使用のためのBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物であって、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたりBifidobacterium breve MCC1274(FERM BP-11175)1.0×106~1.0×1012CFUを経口投与される量のBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物。
[19] 前記対象が軽度認知障害と診断されたものである、[18]に記載の培養物。
[20] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象における脳萎縮抑制効果を表示した、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を含む飲食品。
[21] 前記飲食品が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×109~1.0×1011CFUとなるよう摂取される量の前記培養物を含む、[20]に記載の飲食品。
[22] 前記対象が軽度認知障害と診断されたものである、[20]又は[21]に記載の飲食品。
[23] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に摂取される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用食品。
[24] 前記脳萎縮抑制用食品が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×109~1.0×1011CFUとなるよう摂取される量の前記培養物を含む、[23]に記載の脳萎縮抑制用食品。
[25] 前記対象が軽度認知障害と診断されたものである、[23]又は[24]に記載の脳萎縮抑制用食品。
[26] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象が摂取するための、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用サプリメント。
[27] 前記脳萎縮抑制用サプリメントが、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×109~1.0×1011CFUとなるよう摂取される量の前記培養物を含む、[26]に記載の脳萎縮抑制用サプリメント。
[28] 前記対象が軽度認知障害と診断されたものである、[24]又は[25]に記載の脳萎縮抑制用サプリメント。
[29] 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与するための、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用医薬。
[30] 前記脳萎縮抑制用医薬が、前記対象に1日あたりビフィドバクテリウム・ブレーベ MCC1274(FERM BP-11175)が1.0×109~1.0×1011CFUとなるよう経口投与される量の前記培養物を含む、[29]に記載の脳萎縮抑制用医薬。
[31] 前記対象が軽度認知障害と診断されたものである、[29]又は[30]に記載の脳萎縮抑制用医薬。
Claims (11)
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制剤。
- Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与することを含む脳萎縮の抑制方法。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象の脳萎縮の抑制における使用のためのBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される脳萎縮抑制剤を製造するための、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の使用。
- Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制剤であって、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたり前記Bifidobacterium breve MCC1274(FERM BP-11175)が1.0×106~1.0×1012CFUを経口投与される量のBifidobacterium breve MCC1274(FERM BP-11175)を含む脳萎縮抑制剤。
- Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物の脳萎縮抑制有効量を、脳萎縮抑制を必要とする健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたり前記Bifidobacterium breve MCC1274(FERM BP-11175)1.0×106~1.0×1012CFUを経口投与することを含む脳萎縮の抑制方法。
- 脳萎縮の抑制における使用のためのBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物であって、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に1日あたりBifidobacterium breve MCC1274(FERM BP-11175)1.0×106~1.0×1012CFUを経口投与される量のBifidobacterium breve MCC1274(FERM BP-11175)を含む培養物。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象における脳萎縮抑制効果を表示した、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を含む飲食品。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に摂取される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用食品。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に摂取される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用サプリメント。
- 健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与される、Bifidobacterium breve MCC1274(FERM BP-11175)を含む培養物を有効成分とする脳萎縮抑制用医薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020247004901A KR20240033260A (ko) | 2021-10-22 | 2022-10-21 | 뇌위축 억제제, 뇌위축의 억제 방법, 배양물, 배양물의 사용, 음식품, 뇌위축 억제용 식품, 뇌위축 억제용 서플리먼트, 및 뇌위축 억제용 의약 |
CA3235246A CA3235246A1 (en) | 2021-10-22 | 2022-10-21 | Prophylactic agent for brain atrophy, method for preventing brain atrophy, culture, use of culture, food or beverage, food for preventing brain atrophy, supplement for preventing brain atrophy, and medicine for preventing brain atrophy |
AU2022371908A AU2022371908A1 (en) | 2021-10-22 | 2022-10-21 | Prophylactic agent for brain atrophy, method for preventing brain atrophy, culture, use of culture, food or beverage, food for preventing brain atrophy, supplement for preventing brain atrophy, and medicine for preventing brain atrophy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-173451 | 2021-10-22 | ||
JP2021173451A JP2023063132A (ja) | 2021-10-22 | 2021-10-22 | 脳萎縮抑制剤、脳萎縮の抑制方法、培養物、培養物の使用、飲食品、脳萎縮抑制用食品、脳萎縮抑制用サプリメント、及び脳萎縮抑制用医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023068363A1 true WO2023068363A1 (ja) | 2023-04-27 |
Family
ID=86034213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/039307 WO2023068363A1 (ja) | 2021-10-22 | 2022-10-21 | 脳萎縮抑制剤、脳萎縮の抑制方法、培養物、培養物の使用、飲食品、脳萎縮抑制用食品、脳萎縮抑制用サプリメント、及び脳萎縮抑制用医薬 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2023063132A (ja) |
KR (1) | KR20240033260A (ja) |
CN (2) | CN115998774A (ja) |
AU (1) | AU2022371908A1 (ja) |
CA (1) | CA3235246A1 (ja) |
WO (1) | WO2023068363A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6853821B2 (ja) * | 2016-05-31 | 2021-03-31 | 森永乳業株式会社 | 脳機能改善剤 |
JP2021173451A (ja) | 2020-04-22 | 2021-11-01 | 三菱パワー株式会社 | バーナー集合体、ガスタービン燃焼器及びガスタービン |
WO2021256077A1 (ja) * | 2020-06-18 | 2021-12-23 | 森永乳業株式会社 | 認知機能改善剤、認知機能維持剤、海馬機能改善剤及び海馬機能維持剤 |
-
2021
- 2021-10-22 JP JP2021173451A patent/JP2023063132A/ja active Pending
-
2022
- 2022-10-21 CN CN202211296401.7A patent/CN115998774A/zh active Pending
- 2022-10-21 CA CA3235246A patent/CA3235246A1/en active Pending
- 2022-10-21 AU AU2022371908A patent/AU2022371908A1/en active Pending
- 2022-10-21 CN CN202211565457.8A patent/CN115998775A/zh active Pending
- 2022-10-21 KR KR1020247004901A patent/KR20240033260A/ko unknown
- 2022-10-21 WO PCT/JP2022/039307 patent/WO2023068363A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6853821B2 (ja) * | 2016-05-31 | 2021-03-31 | 森永乳業株式会社 | 脳機能改善剤 |
JP2021173451A (ja) | 2020-04-22 | 2021-11-01 | 三菱パワー株式会社 | バーナー集合体、ガスタービン燃焼器及びガスタービン |
WO2021256077A1 (ja) * | 2020-06-18 | 2021-12-23 | 森永乳業株式会社 | 認知機能改善剤、認知機能維持剤、海馬機能改善剤及び海馬機能維持剤 |
Non-Patent Citations (7)
Title |
---|
"the Diagnostic and Statistical Manual of Mental Disorders", 2013, THE AMERICAN PSYCHIATRIC ASSOCIATION |
BERNIER FRANCOIS, OHNO KAZUYA, KATSUMATA NORIKO, SHIMIZU TAKASHI, XIAO JINZHONG: "Association of Plasma Hemoglobin A1c with Improvement of Cognitive Functions by Probiotic Bifidobacterium breve Supplementation in Healthy Adults with Mild Cognitive Impairment", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 81, no. 2, 18 May 2021 (2021-05-18), NL , pages 493 - 497, XP093059372, ISSN: 1387-2877, DOI: 10.3233/JAD-201488 * |
FOOD LABELING ACT, no. 70, 2013 |
HIROSHI MATSUDA: "III. Learning Image Statistic Software - Acquisition Method, Characteristics, Utility, Problems, 1. Including VSRAD-DARTEL", vol. 26, 25 December 2010, INNERVISION, INNERVISION CO., LTD., pages: 29 - 32 |
KAZUYA OHNO ET AL.: "Intestinal bacteria and brain function, Possibility of cognitive function improvement by Bifidobacterium", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, BIOMEDICAL DRUGS PUBLICATION, JP, vol. 276, no. 11, 13 March 2021 (2021-03-13), JP , pages 1070 - 1072, XP009545628, ISSN: 0039-2359 * |
ORDER OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE OF JAPAN, no. 86, 30 April 2003 (2003-04-30) |
XIAO JINZHONG, KATSUMATA NORIKO, BERNIER FRANCOIS, OHNO KAZUYA, YAMAUCHI YUKI, ODAMAKI TOSHITAKA, YOSHIKAWA KENJI, ITO KUMIE, KANE: "Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 77, no. 1, 1 September 2020 (2020-09-01), NL , pages 139 - 147, XP055895676, ISSN: 1387-2877, DOI: 10.3233/JAD-200488 * |
Also Published As
Publication number | Publication date |
---|---|
KR20240033260A (ko) | 2024-03-12 |
CN115998774A (zh) | 2023-04-25 |
JP2023063132A (ja) | 2023-05-09 |
AU2022371908A1 (en) | 2024-05-02 |
CA3235246A1 (en) | 2023-04-27 |
CN115998775A (zh) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7157196B2 (ja) | 脳機能改善剤 | |
JP7280069B2 (ja) | 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7323510B2 (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP2023014246A (ja) | 認知機能改善剤、認知機能維持剤、海馬機能改善剤及び海馬機能維持剤 | |
WO2023068363A1 (ja) | 脳萎縮抑制剤、脳萎縮の抑制方法、培養物、培養物の使用、飲食品、脳萎縮抑制用食品、脳萎縮抑制用サプリメント、及び脳萎縮抑制用医薬 | |
WO2023234166A1 (ja) | 抗てんかん用組成物 | |
JP2020180094A (ja) | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22883665 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20247004901 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247004901 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022371908 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235246 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 810262 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024007439 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022371908 Country of ref document: AU Date of ref document: 20221021 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022883665 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022883665 Country of ref document: EP Effective date: 20240522 |